{"id":"NCT00710866","sponsor":"British Columbia Centre for Disease Control","briefTitle":"Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and Reactogenicity","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-08","primaryCompletion":"2009-03","completion":"2009-03","firstPosted":"2008-07-08","resultsPosted":"2011-08-04","lastUpdate":"2011-08-04"},"enrollment":262,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)","otherNames":["VAXIGRIP®"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the antibody response and reaction rates in children age 6-23 months when they are given either the currently recommended schedule of two 0.25ml doses of influenza vaccine one month apart or two 0.5ml doses of influenza vaccine, one month apart.","primaryOutcome":{"measure":"Seroprotection Rate Infants (6-11 Months)-A/Brisbane/59/07(H1N1)","timeFrame":"27-46 days after the second dose","effectByArm":[{"arm":"0.5mL VAXIGRIP®","deltaMin":41,"sd":null},{"arm":"0.25mL VAXIGRIP®","deltaMin":34,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":5,"countries":["Canada"]},"refs":{"pmids":["21857263","21768314"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":124},"commonTop":["Irritability","Sleep disturbance","Decreased appetite","Drowsiness","Tenderness"]}}